4 results
The Primary Objectives for the study are:* Demonstrate the non-inferiority (NI) of lefamulin versus comparator with respect to the Early Clinical Response (96 ± 24 hours after the first dose of study drug) in the Intent to Treat (ITT) Analysis Set (…
To demonstrate in a phase III study that the addition of the monoclonal anti-T cell antibody alemtuzumab added to standard CHOP chemotherapy followed by autologous stam cell transplantation will increase the response, event-free survival,…
To determine the effectiveness of the currently recommended treatment regimens.
Primary ObjectiveTo generate evidence demonstrating the domain specification (via modern psychometric methods), reliability, validity, and responsiveness (within-subject meaningful change) of the patient-reported outcome (PRO) endpoints Secondary…